Although a history of smoking and the coexistence of emphysema were negatively associated with the frequency of EGFR mutations, these clinical factors did not affect the prognosis of the patients with EGFR mutations treated with gefitinib. This evidence concerns the gene EGFR and pulmonary emphysema.